Correction to: Drugs - Real World Outcomes (2020). 10.1007/s40801-020-00183-x {#Sec1}
=============================================================================

Changes within text are indicated in **bold.**

**Page 1, Abstract, Results section:** The following sentence, which previously read:

"The **oral treprostinil** cohort had 66.9% **lower** total PAH-related healthcare costs **(mean difference − \$75,183; 95% confidence interval \[CI\] − 102,584 to − 49,771)** and 70.6% **lower** PAH-related pharmacy costs **(mean difference − \$76,439; 95% CI − 104,512 to − 51,458)** than the **selexipag** cohort, with similar differences in all-cause healthcare and pharmacy costs."

should read:

"The **selexipag** cohort had 66.9% **higher** total PAH-related healthcare costs **(mean difference \$75,183; 95% confidence interval \[CI\] 49,771 to 102,584)** and 70.6% **higher** PAH-related pharmacy costs **(mean difference \$76,439; 95% CI 51,458 to 104,512)** than the **oral treprostinil** cohort, with similar differences in all-cause healthcare and pharmacy costs."

**Page 3, Methods, Section 2.2, top of column 2, lines 1--2:** The following sentence that previously read:

"PAH-related HCRU was identified using PH diagnosis codes in **any position**."

should read:

"PAH-related HCRU was identified using PH diagnosis codes in **the primary diagnosis code field**."

**Page 4, Results section, column 1, paragraph 1, lines 18--22:** The following sentence that previously read:

"There was a **10%** difference in the proportion of patients who underwent RHC in the 6 months prior to being prescribed oral prostacyclin, although this difference did not meet statistical significance (47.7 vs. 36.5% for oral treprostinil and selexipag, respectively; *p* = 0.07)."

should read:

"There was an **11.2% absolute** difference in the proportion of patients who underwent RHC in the 6 months prior to being prescribed oral prostacyclin, although this difference did not meet statistical significance (47.7 vs. 36.5% for oral treprostinil and selexipag, respectively; *p* = 0.07)."

**Page 6, Sect. 3.3 Healthcare Resource Use and Costs, column 1, paragraph 2, lines 7--10:** The following sentence that previously read:

"Notably, a higher proportion of patients in the oral treprostinil cohort received RHC during the post-index period compared with the selexipag cohort (**13.2** vs. 5.6%, respectively; *p* = 0.039)."

should read:

"Notably, a higher proportion of patients in the oral treprostinil cohort received RHC during the post-index period compared with the selexipag cohort (**13.1** vs. 5.6%, respectively; *p* = 0.039)."

**Page 6, Sect. 3.3 Healthcare Resource Use and Costs, column 2, last paragraph:** The following sentence that previously read:

"After adjustment for covariates, treatment with **oral treprostinil** was associated with 51.4% **lower** total all-cause healthcare costs than treatment with **selexipag(difference in mean − \$73,680; 95% confidence interval \[CI\] − 103,702 to − 43,963) (Fi**g. 4). This difference in all-cause healthcare costs was largely driven by all-cause pharmacy costs, which were 68.2% **lower** in patients being treated with **oral treprostinil** than in those being treated with **selexipag(difference in mean − \$77,654; 95% CI − 105,392 to − 52,118)**. Treatment with **oral treprostinil** was associated with 66.9% **lower** total PAH-related healthcare costs compared with being treated with **selexipag(difference in mean − \$75,183; 95% CI − 102,584 to − 49,771)**. Differences in PAH-related healthcare costs were largely driven by PAH-related pharmacy costs, which were 70.62% **lower** in patients treated with **oral treprostinil** than in those treated with **selexipag(difference in mean − \$76,439; 95% CI − 104,512 to − 51,458)**."

should read:

"After adjustment for covariates, treatment with **selexipag** was associated with 51.4% **higher** total all-cause healthcare costs than treatment with **oral treprostinil(difference in mean \$73,680; 95% confidence interval \[CI\] \$43,963 to \$103,702)** (Fig. 4). This difference in all-cause healthcare costs was largely driven by all-cause pharmacy costs, which were 68.2% **higher** in patients being treated with **selexipag** than in those being treated with **oral treprostinil(difference in mean \$77,654; 95% CI \$52,118 to \$105,392)**. Treatment with **selexipag** was associated with 66.9% **higher** total PAH-related healthcare costs compared with being treated with **oral treprostinil(difference in mean \$75,183; 95% CI \$49,771 to \$102,584)**. Differences in PAH-related healthcare costs were largely driven by PAH-related pharmacy costs, which were 70.62% **higher** in patients treated with **selexipag** than in those treated with **oral treprostinil(difference in mean \$76,439; 95% CI \$51,458 to \$104,512)**."

**Page 7, Table 2, 'Healthcare resource utilization during the post-index period':** The cell entry in the '*p* value' column, 'Inpatient visits' row, which was previously blank, should read "0.073"

**Page 8, Discussion section, column 1, first paragraph, lines 9--19:** The following sentence that previously read:

"Results suggest that treatment with **oral treprostinil** was associated with 51.4% **lower** total all-cause healthcare costs compared with treatment with **selexipag**, and this was largely driven by all-cause pharmacy costs, which were 68.2% **lower** in patients treated with **oral treprostinil** than in those treated with **selexipag**. Treatment with **oral treprostinil** was associated with 66.9% **lower** total PAH-related healthcare costs compared with treatment with **selexipag**, again largely driven by 70.6% **lower** PAH-related pharmacy costs in patients being treated with **oral treprostinil** than in those being treated with **selexipag**."

should read:

"Results suggest that treatment with **selexipag** was associated with 51.4% **higher** total all-cause healthcare costs compared with treatment with **oral treprostinil**, and this was largely driven by all-cause pharmacy costs, which were 68.2% **higher** in patients treated with **selexipag** than in those treated with **oral treprostinil**. Treatment with **selexipag** was associated with 66.9% **higher** total PAH-related healthcare costs compared with treatment with **oral treprostinil**, again largely driven by 70.6% **higher** PAH-related pharmacy costs in patients being treated with **selexipag** than in those being treated with **oral treprostinil**."
